Curcumin binds to the α-helical intermediate and to the amyloid form of prion protein - A new mechanism for the inhibition of PrPSc accumulation

Journal of Neurochemistry

Volumn 104, Issue 6, 2008, Pages 1553-1564

  Hafner Bratkovič, Iva ^b   Gašperšič, Jernej ^b   Šmid, Lojze M ^b   Bresjanac, Mara ^b   Jerala, Roman ^a,b  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Amyloid; Congo red; Curcumin; Intermediate; Oligomer; Prion

Indexed keywords

AMYLOID; CONGO RED; CURCUMIN; OLIGOMER; PRION PROTEIN; PROTEIN ANTIBODY; THIOFLAVINE;

ALPHA HELIX; ANIMAL TISSUE; ARTICLE; CHIRALITY; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DRUG MECHANISM; HUMAN; IN VITRO STUDY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PH; PRION DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; STOICHIOMETRY;

AMYLOID; BINDING, COMPETITIVE; CEREBELLUM; CIRCULAR DICHROISM; CREUTZFELDT-JAKOB SYNDROME; CURCUMIN; DRUG DESIGN; HUMANS; PROTEIN STRUCTURE, SECONDARY; PRPSC PROTEINS; STEREOISOMERISM;

EID: 39849110292     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.05105.x     Document Type: Article

References (64)

1. Agdeppa E. D., Kepe V., Petri A., Satyamurthy N., Liu J., Huang S. C., Small G. W., Cole G. M. and Barrio J. R. (2003) In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F] fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 117, 723-730.
2. Barik A., Priyadarsini K. I. and Mohan H. (2003) Photophysical studies on binding of curcumin to bovine serum albumins. Photochem. Photobiol. 77, 597-603.
3. Baskakov I. V., Legname G., Baldwin M. A., Prusiner S. B. and Cohen F. E. (2002) Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277, 21140-21148.
4. Bresjanac M., Smid L. M., Vovko T. D., Petric A., Barrio J. R. and Popovic M. (2003) Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)( methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. J. Neurosci. 23, 8029-8033.
5. Breydo L., Bocharova O. V. and Baskakov I. V. (2005) Semiautomated cell-free conversion of prion protein: applications for highthroughput screening of potential antiprion drugs. Anal. Biochem. 339, 165-173.
6. Carter D. B. and Chou K. C. (1998) A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol. Aging 19, 37-40.
7. Cashman N. R. and Caughey B. (2004) Prion diseases - close to effective therapy? Nat. Rev. Drug Discov. 3, 874-884.
8. Caughey B., Ernst D. and Race R. E. (1993) Congo red inhibition of scrapie agent replication. J. Virol. 67, 6270-6272.
9. Caughey B., Brown K., Raymond G. J., Katzenstein G. E. and Thresher W. (1994) Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and Congo red [corrected]. J. Virol. 68, 2135-2141.
10. Caughey B., Raymond L. D., Raymond G. J., Maxson L., Silveira J. and Baron G. S. (2003) Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol. 77, 5499-5502.
11. Chainani-Wu N. (2003) Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa). J. Altern. Complement. Med. 9, 161-168.
12. Chandra V., Pandav R., Dodge H. H., Johnston J. M., Belle S. H., DeKosky S. T. and Ganguli M. (2001) Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 57, 985-989.
13. Dzwolak W. and Pecul M. (2005) Chiral bias of amyloid fibrils revealed by the twisted conformation of thioflavin T: an induced circular dichroism/DFT study. FEBS Lett. 579, 6601-6603.
14. Eghiaian F. (2005) Structuring the puzzle of prion propagation. Curr. Opin. Struct. Biol. 15, 724-730.
15. Findeis M. A. (2000) Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim. Biophys. Acta 1502, 76-84.
16. Frid P., Anisimov S. V. and Popovic N. (2007) Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 53, 135-160.
17. Garcea G., Jones D. J., Singh R., Dennison A. R., Farmer P. B., Sharma R. A., Steward W. P., Gescher A. J. and Berry D. P. (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 90, 1011-1015.
18. Garcia-Alloza M., Borrelli L. A., Rozkalne A., Hyman B. T. and Bacskai B. J. (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 102, 1095-1104.
19. Gauthier T. D., Shane E. C., Guerin W. F., Seitz W. R. and Grant C. L. (1986) Fluorescence quenching method for determining equilibrium- constants for polycyclic aromatic-hydrocarbons binding to dissolved humic materials. Environ. Sci. Technol. 20, 1162-1166.
20. Gerber R., Tahiri-Alaoui A., Hore P. J. and James W. (2007) Oligomerization of the human prion protein proceeds via a molten globule intermediate. J. Biol. Chem. 282, 6300-6307.
21. Giri R. K., Rajagopal V. and Kalra V. K. (2004) Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J. Neurochem. 91, 1199-1210.
22. Govaerts C., Wille H., Prusiner S. B. and Cohen F. E. (2004) Evidence for assembly of prions with left-handed beta-helices into trimers. Proc. Natl Acad. Sci. USA 101, 8342-8347.
23. Gradisar H., Keber M. M., Pristovsek P. and Jerala R. (2007) MD-2 as the target of curcumin in the inhibition of response to LPS. J. Leukoc. Biol. 82, 968-974.
24. Harada N. N. and Nakanishi K. (1983) Circular Dichroic Spectroscopy - Exciton Coupling in Organic Stereochemistry. University Science Books, Mill Valley, CA.
25. Hirohata M., Ono K., Naiki H. and Yamada M. (2005) Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 49, 1088-1099.
26. Ingrosso L., Ladogana A. and Pocchiari M. (1995) Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 69, 506-508.
27. Ishikawa K., Doh-ura K., Kudo Y., Nishida N., Murakami-Kubo I., Ando Y., Sawada T. and Iwaki T. (2004) Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 85, 1785-1790.
28. Jansen K., Schafer O., Birkmann E., Post K., Serban H., Prusiner S. B. and Riesner D. (2001) Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form. Biol. Chem. 382, 683-691.
29. Jung K. K., Lee H. S., Cho J. Y., Shin W. C., Rhee M. H., Kim T. G., Kang J. H., Kim S. H., Hong S. and Kang S. Y. (2006) Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide- activated primary microglia. Life Sci. 79, 2022-2031.
30. Kang G., Kong P. J., Yuh Y. J., Lim S. Y., Yim S. V., Chun W. and Kim S. S. (2004) Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor jb bindings in BV2 microglial cells. J. Pharmacol. Sci. 94, 325-328.
31. Kim H. Y., Park E. J., Joe E. H. and Jou I. (2003) Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol. 171, 6072-6079.
32. Kim G. Y., Kim K. H., Lee S. H., Yoon M. S., Lee H. J., Moon D. O., Lee C. M., Ahn S. C., Park Y. C. and Park Y. M. (2005) Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J. Immunol. 174, 8116-8124.
33. Klunk W. E., Jacob R. F. and Mason R. P. (1999) Quantifying amyloid by Congo red spectral shift assay. Methods Enzymol. 309, 285-305.
34. Klunk W. E., Engler H., Nordberg A. et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55, 306-319.
35. Kocisko D. A., Engel A. L., Harbuck K., Arnold K. M., Olsen E. A., Raymond L. D., Vilette D. and Caughey B. (2005) Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie. Neurosci. Lett. 388, 106-111.
36. Lee V. M. (2002) Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol. Aging 23, 1039-1042.
37. LeVine H. III (2005a) Mechanism of A beta(1-40) fibril-induced fluorescence of (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene (K114). Biochemistry 44, 15937-15943.
38. LeVine H. III (2005b) Multiple ligand binding sites on A beta(1-40) fibrils. Amyloid 12, 5-14.
39. Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A. and Cole G. M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377.
40. Luhrs T., Zahn R. and Wuthrich K. (2006) Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. J. Mol. Biol. 357, 833-841.
41. Mason J. M., Kokkoni N., Stott K. and Doig A. J. (2003) Design strategies for anti-amyloid agents. Curr. Opin. Struct. Biol. 13, 526-532.
42. Milhavet O., Mange A., Casanova D. and Lehmann S. (2000) Effect of Congo red on wild-type and mutated prion proteins in cultured cells. J. Neurochem. 74, 222-230.
43. Novitskaya V., Bocharova O. V., Bronstein I. and Baskakov I. V. (2006a) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281, 13828-13836.
44. Novitskaya V., Makarava N., Bellon A., Bocharova O. V., Bronstein I. B., Williamson R. A. and Baskakov I. V. (2006b) Probing the conformation of the prion protein within a single amyloid fibril using a novel immunoconformational assay. J. Biol. Chem. 281, 15536-15545.
45. Ono K., Hasegawa K., Naiki H. and Yamada M. (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 75, 742-750.
46. Prusiner S. B. (1998) Prions. Proc. Natl Acad. Sci. USA 95, 13363-13383.
47. Ryu E. K., Choe Y. S., Lee K. H., Choi Y. and Kim B. T. (2006) Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J. Med. Chem. 49, 6111-6119.
48. Shoghi-Jadid K., Small G. W., Agdeppa E. D. et al. (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24-35.
49. Silveira J. R., Raymond G. J., Hughson A. G., Race R. E., Sim V. L., Hayes S. F. and Caughey B. (2005) The most infectious prion protein particles. Nature 437, 257-261.
50. Stefani M. (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta 1739, 5-25.
51. Swietnicki W., Morillas M., Chen S. G., Gambetti P. and Surewicz W. K. (2000) Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry 39, 424-431.
52. Swillens S. (1995) Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis. Mol. Pharmacol. 47, 1197-1203.
53. Tattum M. H., Cohen-Krausz S., Khalili-Shirazi A., Jackson G. S., Orlova E. V., Collinge J., Clarke A. R. and Saibil H. R. (2006) Elongated oligomers assemble into mammalian PrP amyloid fibrils. J. Mol. Biol. 357, 975-985.
54. Turnell W. G. and Finch J. T. (1992) Binding of the dye Congo red to the amyloid protein pig insulin reveals a novel homology amongst amyloid-forming peptide sequences. J. Mol. Biol. 227, 1205-1223.
55. Verhoeff N. P.,Wilson A. A., Takeshita S., Trop L., Hussey D., Singh K., Kung H. F., Kung M. P. and Houle S. (2004) In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12, 584-595.
56. White A. R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J. and Hawke S. (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83.
57. Wille H., Michelitsch M. D., Guenebaut V., Supattapone S., Serban A., Cohen F. E., Agard D. A. and Prusiner S. B. (2002) Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl Acad. Sci. USA 99, 3563-3568.
58. Xu Y. X., Pindolia K. R., Janakiraman N., Noth C. J., Chapman R. A. and Gautam S. C. (1997) Curcumin, a compound with antiinflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp. Hematol. 25, 413-422.
59. Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901.
60. Zahn R., von Schroetter C. and Wuthrich K. (1997) Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding. FEBS Lett. 417, 400-404.
61. Zsila F., Bikadi Z. and Simonyi M. (2001) Induced chirality upon crocetin binding to human serum albumin: origin and nature. Tetrahedron Asymmetry 12, 3125-3137.
62. Zsila F., Bikadi Z. and Simonyi M. (2003a) Unique, pH-dependent biphasic band shape of the visible circular dichroism of curcuminserum albumin complex. Biochem. Biophys. Res. Commun. 301, 776-782.
63. Zsila F., Bikadi Z. and Simonyi M. (2003b) Molecular basis of the cotton effects induced by the binding of curcumin to human serum albumin. Tetrahedron Asymmetry 14, 2433-2444.
64. Zsila F., Bikadi Z. and Simonyi M. (2004) Induced circular dichroism spectra reveal binding of the antiinflammatory curcumin to human alpha1-acid glycoprotein. Bioorg. Med. Chem. 12, 3239-3245.